Brief: Pliant Therapeutics Announces FDA Clearance Of Investigational NDA For PLN-101095
Feb 2 (Reuters) - Pliant Therapeutics Inc PLRX.O :
* PLIANT THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR PLN-101095, A NOVEL INTEGRIN INHIBITOR
FOR THE TREATMENT OF SOLID TUMORS
Source text for Eikon: ID:nGNX9pLXRG
Further company coverage: PLRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals